医学
胃肠病学
熊去氧胆酸
内科学
耐火材料(行星科学)
泼尼松龙
骨质疏松症
原发性胆汁性肝硬化
临床试验
胆汁酸
联合疗法
作者
T T Yao,Jian-Dan Qian,Gui-Qiang Wang
标识
DOI:10.1016/j.medcli.2020.03.013
摘要
Abstract Background and Aim To explore the efficacy treatment regimen in refractory PBC. Methods Triple treatment including ursodeoxycholic acid, prednisolone and immunosuppressant was prescribed to 47 refractory patients. Biochemistries, immune parameters, non-invasive liver fibrosis assessments were measured during follow-up. Results Triple therapy resulted in significant decrease in ALP, GGT, ALT, AST, TBIL, ALB, IgG, IgM, APRI, FIB-4 and S-INDEX. The biochemical cumulative normalization rates of ALP and other biochemical parameters were higher in long-term follow-up. Poor outcome was observed in patients with lower ALB, higher TBIL, PT, sp100 positivity and advanced liver pathology at baseline. Osteoporosis and bone fracture were observed in 15% patients. Conclusions Triple therapy is associated with marked decrease and normalization of ALP and other parameters. ALB, TBIL, PT, sp100 and pathology were related with poor outcome. Osteoporosis should be closely monitored.
科研通智能强力驱动
Strongly Powered by AbleSci AI